GSK to acquire RAPT Therapeutics for $2.2bn.

GSK, a global biopharmaceutical company, agreed to acquire RAPT Therapeutics, a clinical-stage immunology-based biopharmaceutical company, for $2.2bn. “The addition of ozureprubart brings another promising new, potential best-in-class treatment to GSK’s pipeline. Food allergies cause severe health impacts to patients with existing treatment requiring injections as frequently as every 2 weeks. Ozureprubart offers the opportunity to bring sustained protection to patients with dosing every 12 weeks, and is consistent with our approach to acquire assets that address validated targets and where there is clear unmet medical need,” Tony Wood, GSK Chief Scientific Officer.